Citadel Advisors’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,700
| Closed | -$61.2K | – | 13455 |
|
|
2025
Q3 | $61.2K | Buy |
+15,700
| New | +$64.4K | ﹤0.01% | 12093 |
|
|
2025
Q1 | – | Sell |
-270
| Closed | -$1.81K | – | 15092 |
|
|
2024
Q4 | $1.81K | Sell |
270
-1,110
| -80% | -$8.27K | ﹤0.01% | 14146 |
|
|
2024
Q3 | $10.7K | Buy |
1,380
+1,060
| +331% | +$6.39K | ﹤0.01% | 13191 |
|
|
2024
Q2 | $1.92K | Buy |
320
+60
| +23% | +$456 | ﹤0.01% | 13762 |
|
|
2024
Q1 | $2.34K | Sell |
260
-9,780
| -97% | -$89.1K | ﹤0.01% | 14014 |
|
|
2023
Q4 | $95.1K | Buy |
10,040
+160
| +2% | +$1.41K | ﹤0.01% | 10992 |
|
|
2023
Q3 | $118K | Sell |
9,880
-120
| -1% | -$2.13K | ﹤0.01% | 10688 |
|
|
2023
Q2 | $245K | Buy |
10,000
+10
| +0.1% | +$260 | ﹤0.01% | 9448 |
|
|
2023
Q1 | $313K | Buy |
9,990
+490
| +5% | +$28.4K | ﹤0.01% | 9299 |
|
|
2022
Q4 | $669K | Sell |
9,500
-4,950
| -34% | -$367K | ﹤0.01% | 7644 |
|
|
2022
Q3 | $1.24M | Sell |
14,450
-8,280
| -36% | -$804K | ﹤0.01% | 6521 |
|
|
2022
Q2 | $1.88M | Buy |
22,730
+17,700
| +352% | +$1.56M | ﹤0.01% | 5657 |
|
|
2022
Q1 | $836K | Buy |
5,030
+3,110
| +162% | +$446K | ﹤0.01% | 8121 |
|
|
2021
Q4 | $321K | Buy |
+1,920
| New | +$217K | ﹤0.01% | 10775 |
|
|
2020
Q4 | – | Sell |
-1,020
| Closed | -$49K | – | 11242 |
|
|
2020
Q3 | $49K | Buy |
+1,020
| New | +$48.8K | ﹤0.01% | 9609 |
|
Citadel Advisors's KZR Position: Q2 2026 in Review
Citadel Advisors sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 59,403 shares — an estimated $441K sold.
Citadel Advisors first reported a position in KZR in Q1 2019 and held it in 26 quarters. The position peaked at $4.14M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Citadel Advisors reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 59,403 Kezar Life Sciences shares in Q2 2026, an estimated $441K.
- Citadel Advisors first reported a position in Kezar Life Sciences in Q1 2019 and held it in 26 quarters.
- Citadel Advisors's Kezar Life Sciences position peaked at $4.14M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.